97 studies found for:    CLN1
Show Display Options
Rank Status Study
1 Completed Study of HuCNS-SC Cells in Patients With Infantile or Late Infantile Neuronal Ceroid Lipofuscinosis (NCL)
Condition: Neuronal Ceroid Lipofuscinosis
Interventions: Procedure: Surgery to implant human CNS stem cells (HuCNS-SC);   Drug: Medication to suppress the immune system
2 Completed W0261-101: A Phase 1, Single Center, Randomized, Open-Label Study to Evaluate the Bioavailability of Clindamycin From Clindamycin 1%-Benzoyl Peroxide 3% Gel, Topical Gel (Clindamycin 1%- Benzoyl Peroxide 5%), and Once Daily Gel (Clindamycin 1%-Benzoyl Peroxide 5%) in Subjects With Acne
Condition: Acne Vulgaris
Intervention: Drug: Clindamycin 1%-Benzoyl Peroxide (BPO) 3% Gel,
3 Completed Cystagon to Treat Infantile Neuronal Ceroid Lipofuscinosis
Condition: Infantile Neronal Ceroid Lipofuscinosis
Intervention: Drug: Cystagon
4 Recruiting Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors
Condition: Cancer
Intervention: Drug: SNX-5422
5 Recruiting Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies
Condition: Cancer
Intervention: Drug: SNX-5422
6 Recruiting Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers
Condition: Cancer
Intervention: Drug: SNX-5422
7 Completed Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies
Condition: Cancer
Intervention: Drug: SNX-5422
8 Active, not recruiting Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma
Condition: Cancer
Intervention: Drug: SNX-5422
9 Completed Effects of 2006-RD-05 on Salivary and Serum Immunoglobulin A (IgA) Levels in Healthy Subjects
Condition: Healthy
Interventions: Dietary Supplement: 2006-RD-05;   Dietary Supplement: Placebo
10 Completed Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies
Condition: Hematologic Neoplasms
Intervention: Drug: SNX-5422
11 Completed Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies
Condition: Cancer
Intervention: Drug: SNX-5422
12 Recruiting A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Intracerebroventricular BMN 190 in Patients With Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2) Disease
Conditions: Jansky-Bielschowsky Disease;   Batten Disease;   Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2;   CLN2 Disease
Intervention: Biological: BMN 190
13 Terminated
Has Results
A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGel™ in Subjects With Recurrent Glioma
Conditions: Glioblastoma Multiforme;   Brain Neoplasms
Intervention: Drug: OncoGel (ReGel/Paclitaxel)
14 Completed
Has Results
Endometrial Safety Study
Condition: Postmenopause
Interventions: Drug: 0.25mg DRSP / 0.5mg E2 (BAY86-4891);   Drug: 0.5mg NETA / 1.0mg E2 (Activella)
15 Completed A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma
Condition: Recurrent or Progressive Malignant Glioma
Intervention: Drug: ANG1005
16 Completed A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain Cancer
Condition: Advanced Solid Tumors With and Without Brain Metastases
Intervention: Drug: ANG1005
17 Not yet recruiting SHTC - EUROPE-1 Synergo Hyperthermia-Chemotherapy by European Urologists' Research Operation Preserving Evolution Study I
Conditions: Urinary Bladder Neoplasms;   Urologic Neoplasms;   Urogenital Neoplasms;   Neoplasms;   Neoplasms by Site;   Urinary Bladder Diseases;   Urologic Diseases
Interventions: Device: Synergo + MMC;   Drug: Bacillus Calmette-Guérin
18 Completed Phase II, Randomized, Placebo-controlled Trial in Patients With Charcot-marie-tooth Disease Type 1A
Conditions: Charcot-Marie-Tooth Disease;   Hereditary Neuropathy With Liability to Pressure Palsies;   Genetic Disorders;   Tooth Disorders
Interventions: Drug: PXT3003;   Other: Placebo
19 Completed Effectiveness of an HIV Vaccine in HIV-Negative Adults in North America Who Are at Risk of HIV Infection
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: MN rgp120/HIV-1 and GNE8 rgp120/HIV-1
20 Terminated Single-Dose Cross-Over Study of the Effects of Albuterol-HFA in Exercise Induced Bronchoconstriction
Conditions: Asthma;   Bronchospasm
Interventions: Drug: albuterol (Armstrong Albuterol HFA);   Drug: Albuterol Sulfate (Provenetil-HFA);   Drug: Placebo-HFA

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years